How a Single eGFR Change Is Exposing the Clinical Trial Industry’s Embedded Patient Bias Problem
A new real-world evidence study shows that removing race from the kidney function algorithm resulted in 5.3 more transplants...
The UK Just Made a $64M Bet That the U.S. Is Too Distracted to Match
While Washington debates FDA staffing cuts and budget rescissions, the UK's NIHR has made a $64 million structural investment...
Bourla vs. Prasad: Is Pfizer Defending Science or Defending Its Pipeline?
When Pfizer CEO Albert Bourla publicly calls out a sitting FDA division chief by name, the instinct is to...
Why Big Pharma Clinical Trial Digital Transformation Initiatives Fail
The trial lead sat in a high-stakes protocol review meeting, subtly tilting their laptop screen away from the digital...
How Early-Stage Intelligence Determines Late-Stage Success
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
How Early-Stage Intelligence Determines Late-Stage Success
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
The Seven-Day Miracle: Why the FDA’s New Pathway Could be the End of Randomized Clinical Trials
The parents of Baby K.J. (Kyle Patrick Muldoon, Jr.) didn’t have years to wait for a double-blind, placebo-controlled trial....
Data Gluttony? Why Big Pharma is Addicted to 5.9 Million Useless Clinical Trial Datapoints
The lead site coordinator stared at the tablet, then at the patient, then back at the tablet. They were...
Why Correcting Trial Imaging Errors at Central Review Is Too Late—and Too Expensive
The patient drove two hours each way for the trial, which her oncologist and she believed was her best...
FDA’s National Priority Voucher Program Is Just a Modular PMA Rebrand, With Risks
In June 2025, FDA announced its new Commissioner’s National Priority Voucher (CNPV) program, a headline-grabbing reform that promises to...